BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1701 related articles for article (PubMed ID: 32269119)

  • 21. Broadly neutralizing anti-influenza virus antibodies: enhancement of neutralizing potency in polyclonal mixtures and IgA backbones.
    He W; Mullarkey CE; Duty JA; Moran TM; Palese P; Miller MS
    J Virol; 2015 Apr; 89(7):3610-8. PubMed ID: 25589655
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Mutations in the Hemagglutinin Stalk Domain Do Not Permit Escape from a Protective, Stalk-Based Vaccine-Induced Immune Response in the Mouse Model.
    Roubidoux EK; Carreño JM; McMahon M; Jiang K; van Bakel H; Wilson P; Krammer F
    mBio; 2021 Feb; 12(1):. PubMed ID: 33593972
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Development of Influenza B Universal Vaccine Candidates Using the "Mosaic" Hemagglutinin Approach.
    Sun W; Kirkpatrick E; Ermler M; Nachbagauer R; Broecker F; Krammer F; Palese P
    J Virol; 2019 Jun; 93(12):. PubMed ID: 30944178
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [In vitro Antiviral Activity of Recombinant Antibodies of IgG and IgA Isotypes to Hemagglutinin of the Influenza A Virus].
    Argentova VV; Aliev TK; Zarubaev VV; Klotchenko SA; Shtro AA; Sergeeva MV; Toporova VA; Dolgikh DA; Sveshnikov PG; Vasin VA; Kirpichnikov MP
    Mol Biol (Mosk); 2017; 51(6):927-937. PubMed ID: 29271957
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A VLP vaccine induces broad-spectrum cross-protective antibody immunity against H5N1 and H1N1 subtypes of influenza A virus.
    Wu CY; Yeh YC; Chan JT; Yang YC; Yang JR; Liu MT; Wu HS; Hsiao PW
    PLoS One; 2012; 7(8):e42363. PubMed ID: 22879951
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Influenza Virus Hemagglutinin Stalk-Specific Antibodies in Human Serum are a Surrogate Marker for
    Jacobsen H; Rajendran M; Choi A; Sjursen H; Brokstad KA; Cox RJ; Palese P; Krammer F; Nachbagauer R
    mBio; 2017 Sep; 8(5):. PubMed ID: 28928215
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Influenza Neuraminidase Subtype N1: Immunobiological Properties and Functional Assays for Specific Antibody Response.
    Changsom D; Lerdsamran H; Wiriyarat W; Chakritbudsabong W; Siridechadilok B; Prasertsopon J; Noisumdaeng P; Masamae W; Puthavathana P
    PLoS One; 2016; 11(4):e0153183. PubMed ID: 27054879
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Computationally Optimized Broadly Reactive Antigen Subtype-Specific Influenza Vaccine Strategy Elicits Unique Potent Broadly Neutralizing Antibodies against Hemagglutinin.
    Sautto GA; Kirchenbaum GA; Abreu RB; Ecker JW; Pierce SR; Kleanthous H; Ross TM
    J Immunol; 2020 Jan; 204(2):375-385. PubMed ID: 31811019
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of neutralizing monoclonal antibodies against the pandemic H1N1 virus (2009) using plasmid DNA immunogen.
    Cabral TM; Baig A; Berhane Y; Schmidt L; Hole K; Leith M; Kobasa D; Corbett CR
    J Virol Methods; 2014 Jan; 195():54-62. PubMed ID: 24060631
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mini-HA Is Superior to Full Length Hemagglutinin Immunization in Inducing Stem-Specific Antibodies and Protection Against Group 1 Influenza Virus Challenges in Mice.
    van der Lubbe JEM; Verspuij JWA; Huizingh J; Schmit-Tillemans SPR; Tolboom JTBM; Dekking LEHA; Kwaks T; Brandenburg B; Meijberg W; Zahn RC; Roozendaal R; Kuipers H
    Front Immunol; 2018; 9():2350. PubMed ID: 30369928
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Heterosubtypic neutralizing monoclonal antibodies cross-protective against H5N1 and H1N1 recovered from human IgM+ memory B cells.
    Throsby M; van den Brink E; Jongeneelen M; Poon LL; Alard P; Cornelissen L; Bakker A; Cox F; van Deventer E; Guan Y; Cinatl J; ter Meulen J; Lasters I; Carsetti R; Peiris M; de Kruif J; Goudsmit J
    PLoS One; 2008; 3(12):e3942. PubMed ID: 19079604
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An antibody against a novel and conserved epitope in the hemagglutinin 1 subunit neutralizes numerous H5N1 influenza viruses.
    Oh HL; Akerström S; Shen S; Bereczky S; Karlberg H; Klingström J; Lal SK; Mirazimi A; Tan YJ
    J Virol; 2010 Aug; 84(16):8275-86. PubMed ID: 20519402
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Virus-neutralizing antibody response of mice to consecutive infection with human and avian influenza A viruses.
    Janulíková J; Stropkovská A; Bobišová Z; Košík I; Mucha V; Kostolanský F; Varečková E
    Acta Virol; 2015 Jun; 59(2):166-73. PubMed ID: 26104333
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Evaluation of the immunogenicity and protective effects of a trivalent chimeric norovirus P particle immunogen displaying influenza HA2 from subtypes H1, H3 and B.
    Gong X; Yin H; Shi Y; He X; Yu Y; Guan S; Kuai Z; Haji NM; Haji NM; Kong W; Shan Y
    Emerg Microbes Infect; 2016 May; 5(5):e51. PubMed ID: 27222326
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A human antibody recognizing a conserved epitope of H5 hemagglutinin broadly neutralizes highly pathogenic avian influenza H5N1 viruses.
    Hu H; Voss J; Zhang G; Buchy P; Zuo T; Wang L; Wang F; Zhou F; Wang G; Tsai C; Calder L; Gamblin SJ; Zhang L; Deubel V; Zhou B; Skehel JJ; Zhou P
    J Virol; 2012 Mar; 86(6):2978-89. PubMed ID: 22238297
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Alternative recognition of the conserved stem epitope in influenza A virus hemagglutinin by a VH3-30-encoded heterosubtypic antibody.
    Wyrzucki A; Dreyfus C; Kohler I; Steck M; Wilson IA; Hangartner L
    J Virol; 2014 Jun; 88(12):7083-92. PubMed ID: 24719426
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cross-reactive immunity against influenza viruses in children and adults following 2009 pandemic H1N1 infection.
    Ahmed MS; Jacques LC; Mahallawi W; Ferrara F; Temperton N; Upile N; Vaughan C; Sharma R; Beer H; Hoschler K; McNamara PS; Zhang Q
    Antiviral Res; 2015 Feb; 114():106-12. PubMed ID: 25513756
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Structure of a classical broadly neutralizing stem antibody in complex with a pandemic H2 influenza virus hemagglutinin.
    Dreyfus C; Ekiert DC; Wilson IA
    J Virol; 2013 Jun; 87(12):7149-54. PubMed ID: 23552413
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cross-protective immunity against multiple influenza virus subtypes by a novel modified vaccinia Ankara (MVA) vectored vaccine in mice.
    Brewoo JN; Powell TD; Jones JC; Gundlach NA; Young GR; Chu H; Das SC; Partidos CD; Stinchcomb DT; Osorio JE
    Vaccine; 2013 Apr; 31(14):1848-55. PubMed ID: 23376279
    [TBL] [Abstract][Full Text] [Related]  

  • 40. IgA tetramerization improves target breadth but not peak potency of functionality of anti-influenza virus broadly neutralizing antibody.
    Saito S; Sano K; Suzuki T; Ainai A; Taga Y; Ueno T; Tabata K; Saito K; Wada Y; Ohara Y; Takeyama H; Odagiri T; Kageyama T; Ogawa-Goto K; Multihartina P; Setiawaty V; Pangesti KNA; Hasegawa H
    PLoS Pathog; 2019 Jan; 15(1):e1007427. PubMed ID: 30605488
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 86.